HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

LY2405319

a synthetic peptide based on FGF21

Networked: 6 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Intercellular Signaling Peptides and Proteins: 29768
    - Fibroblast Growth Factors: 2575
      - LY2405319: 6
- Peptides: 82426
  - Intercellular Signaling Peptides and Proteins: 29768
    - Fibroblast Growth Factors: 2575
      - LY2405319: 6
Biological Factors: 2472
- Intercellular Signaling Peptides and Proteins: 29768
  - Fibroblast Growth Factors: 2575
    - LY2405319: 6

Experts

1.	Kharitonenkov, Alexei: 2 articles (09/2013 - 01/2013)
2.	Moller, David E: 2 articles (09/2013 - 01/2013)
3.	Bae, Jae Hyun: 1 article (09/2020)
4.	Lee, Gha Young: 1 article (09/2020)
5.	Lim, Soo: 1 article (09/2020)
6.	Maeng, Hyo Jin: 1 article (09/2020)
7.	Cho, Eun-Hee: 1 article (01/2018)
8.	Choi, Dae Hee: 1 article (01/2018)
9.	Le, Cong Thuc: 1 article (01/2018)
10.	Nguyen, Giang: 1 article (01/2018)

Related Diseases

1.	Fatty Liver 01/01/2016 - "LY2405319 treatment in ob/ob mice on an MCD diet significantly reduced the symptoms of steatohepatitis, as confirmed by Masson's trichrome staining intensity. " 01/01/2018 - "Administration of LY2405319 improved steatohepatitis ameliorated GPR91 and α -SMA production in the liver, decreased succinate concentration in both liver and serum of MCD diet -induced mice. " 01/01/2016 - "Here, we investigated the protective effects of the LY2405319 compound, an engineered FGF21 variant, in a non-alcoholic steatohepatitis (NASH) model using leptin-deficient ob/ob mice and a methionine- and choline-deficient (MCD) diet to induce steatohepatitis. "
2.	Alcoholic Fatty Liver 01/01/2016 - "An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function." 01/01/2016 - "Here, we investigated the protective effects of the LY2405319 compound, an engineered FGF21 variant, in a non-alcoholic steatohepatitis (NASH) model using leptin-deficient ob/ob mice and a methionine- and choline-deficient (MCD) diet to induce steatohepatitis. "
3.	Obesity 09/03/2013 - "Here, we studied the effects of LY2405319 (LY), a variant of FGF21, in a randomized, placebo-controlled, double-blind proof-of-concept trial in patients with obesity and type 2 diabetes. "
4.	Liver Cirrhosis (Hepatic Cirrhosis) 01/01/2018 - "In this study, we evaluated the role of LY2405319, an analogue of FGF21, in hepatic stellate cell (HSC) activation and in a methionine and choline-deficient (MCD)-diet induced mouse model of liver fibrosis. "
5.	Type 2 Diabetes Mellitus (MODY) 09/03/2013 - "The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes." 09/03/2013 - "Here, we studied the effects of LY2405319 (LY), a variant of FGF21, in a randomized, placebo-controlled, double-blind proof-of-concept trial in patients with obesity and type 2 diabetes. "

Related Drugs and Biologics

1.	fibroblast growth factor 21
2.	Methionine (L-Methionine)
3.	Choline (Choline Chloride)
4.	Leptin
5.	Succinic Acid (Succinate)
6.	Glucose (Dextrose)
7.	antineoplaston A10 (A 10)